In the phase IV , open-label , single-arm study NCT01203917 , first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor ( EGFR ) mutation-positive non-small-cell lung cancer ( previously published ) .